

July 9, 2018  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## **Eagle Announces New Patent Issued for Bendamustine Hydrochloride Injection in the U.S.**

TOKYO, Japan, July 9, 2018 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio,") announced today that its U.S. partner, Eagle Pharmaceuticals, Inc. (Headquarters: Woodcliff Lake, NJ, "Eagle") announced on July 3, 2018 that an additional patent has been issued related to BENDEKA<sup>®</sup> by the United States Patent and Trademark Office (USPTO). Eagle's bendamustine liquid formulations are now protected by 14 patents expiring from 2026 to 2033. Under the terms of the license agreement concluded with Eagle in September 2017<sup>(\*)</sup>, SymBio has an exclusive license to develop, market and sell Eagle's bendamustine hydrochloride ready-to-dilute (RTD) and rapid infusion (RI) injection products in Japan.

For Eagle's full press release, please visit the company's website.

<http://investor.eagleus.com/>

With regard to TREAKISYM<sup>®</sup> (bendamustine hydrochloride injection) in Japan, SymBio has completed consultations with the PMDA (Pharmaceuticals and Medical Devices Agency) on the content of the application for marketing authorization for RTD and the design of clinical trials for RI. SymBio aims to launch these liquid formulations in Japan in or after FY2021. In addition, SymBio is conducting Phase 3 trials for the indication of diffuse large B-cell lymphoma (DLBCL), which accounts for approximately one-third of malignant lymphoma, and aims to obtain approval for relapsed/refractory DLBCL in the first half of fiscal 2021. SymBio will continue to steadily implement these initiatives and maximize the business value of TREAKISYM<sup>®</sup> through appropriate life cycle management and the patent protected liquid formulations.

There is no change to the Company's earnings forecast for the year ended December 31, 2018.

(\*)Please refer to SymBio's IR News "Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited" issued on September 21, 2017 for the conclusion of a licensing agreement with Eagle.

[http://www.symbiopharma.com/news\\_e/20170921\\_1e.pdf](http://www.symbiopharma.com/news_e/20170921_1e.pdf)

#### **About Eagle Pharmaceuticals, Inc.**

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle's strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the Company's website at [www.eagleus.com](http://www.eagleus.com).

#### **About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.